Status:

UNKNOWN

A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors

Lead Sponsor:

Guangdong Provincial People's Hospital

Collaborating Sponsors:

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Conditions:

Cancer

Malignant Neoplasm

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The investigators designed and synthesized a novel fibroblast activation protein (FAP) ligand (DOTA-GPFAPI-04) by assembling three functional moieties: a quinoline-based FAP inhibitor for specifically...

Detailed Description

At the beginning of 2022, the National Cancer Center released the latest statistical data showing that the incidence rate of malignant tumors in China reached 293.91/100000, and the mortality rate rea...

Eligibility Criteria

Inclusion

  • Patients with high clinical suspicion of malignant tumors;
  • Those who have undergone endoscopic biopsy or puncture biopsy indicating malignant tumors but have not undergone surgery or chemotherapy;
  • Previous history of malignant tumor surgery, suspected of recurrence or distant metastasis;
  • There is a willingness for puncture biopsy or surgery, and there are no contraindications for puncture biopsy or surgery, and there are no contraindications for anesthesia;
  • Sign an informed consent form and undergo a nuclear medicine examination, without any contraindications, with the ability and willingness to participate in the follow-up plan.

Exclusion

  • Those who cannot tolerate puncture biopsy or surgical contraindications;
  • Those who have undergone radiotherapy and chemotherapy in the past 3 months;
  • Individuals who are allergic to multiple drugs or foods;
  • Those who refuse nuclear medicine examinations;
  • Those who do not agree to sign an informed consent form and are unable or willing to follow up.

Key Trial Info

Start Date :

January 13 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06186427

Start Date

January 13 2024

End Date

December 31 2025

Last Update

January 22 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China, 510080